Drug treatments of levodopa-induced dyskinesias.
Vale
S
S
D000547:Amantadine / Q000627:therapeutic use*; D000978:Antiparkinson Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015259:Dopamine Agents / Q000627:therapeutic use*; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy* / Q000209:etiology; D018691:Excitatory Amino Acid Antagonists / Q000627:therapeutic use*; D006801:Humans; D007980:Levodopa / Q000009:adverse effects* / Q000627:therapeutic use; D018579:Patient Selection; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors; D019782:Riluzole / Q000627:therapeutic use*; D016896:Treatment Outcome
D000978:Antiparkinson Agents; D015259:Dopamine Agents; D018691:Excitatory Amino Acid Antagonists; D016194:Receptors, N-Methyl-D-Aspartate; D007980:Levodopa; D019782:Riluzole; D000547:Amantadine